Ilumya Injectable Product

Phase 3Small molecule

PPsoriasis Treatment Center of Central New Jersey

Ilumya Injectable Product is one of 45 small molecule programs targeting Psoriasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PsoriasisRecruiting

PsoriasisPhase 3

Recruiting

Competition

Competitive Landscape

102 competitors in Psoriasis

#DrugCompanyPhaseTrials

Daliresp

AstraZeneca

Phase 3

5 2

Zasocitinib

Takeda

Phase 3

1 3

D-2570

IInventisBio Co., Ltd

Phase 3

4 4

TAK-279

Takeda

Phase 3

3 5

SYHX1901

CCSPC Ouyi Pharmaceutical Co., Ltd.

Phase 3

2 6

Vunakizumab (IL-17A Inhibitor)

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

1 7

SHR-1314

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

4 8

ICP-488

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

3 9

HS-10374

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3

3 10

IDP-118 Lotion

BBausch Health Americas, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Psoriasis1 trial

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

Recruiting·PPsoriasis Treatment Center of Central New Jersey·Phase 4·NCT04347473·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ilumya Injectable Product. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ilumya Injectable Product compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ilumya Injectable Product. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Psoriasis Treatment Center of Central New Jersey company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPsoriasis Treatment Center of Central New Jersey

Ilumya Injectable Product

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Psoriasis1 trial

References

Drug Info

Quick Facts

Related News